New York, New York--(Newsfile Corp. - February 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Stellantis N.V. ("Stellantis N.V.") (NYSE: STLA) concerning potential violations of the federal securities laws.A review of the timeline highlights a sequence of signals that preceded the February 6 disclosure. On January 31, 2026, Wall Street Zen downgraded STLA to Sell. On February 3, Morgan Stanley followed with a downgrade to Equal-Weight, referencing an "investment ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February 24, 2026) - Faru ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Wealthfront To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Wealthfront stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February 24, 2026) - Faruqi ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Zynex (ZYXIQ) To Contact Him Directly To Discuss Their Options If you purchased or acquired Zynex securities between February 25, 2021 to December 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Br ...

Core Viewpoint - Medpace Holdings, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price despite reporting strong Q4 earnings [1][2]. Financial Performance - Medpace reported Q4 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding Wall Street consensus estimates [2]. - The stock price fell approximately 10% by mid-day and closed down 15.9%, with a trading volume of about $10.2 million during the sell-off, indicating heightened trading activity [2]. Market Reaction - Analysts attributed the stock decline to a bookings shortfall, which overshadowed the positive sales and profit figures [3]. - The book-to-bill ratio missed expectations, leading to concerns about forward demand and a sharp decline in stock price [3]. Institutional Activity - Principal Financial Group reduced its stake in Medpace by 8.4% prior to the earnings release, while Representative David Taylor purchased shares shortly before [4]. Analyst Inquiries - During the Q4 earnings call, analysts raised concerns about booking deterioration and cancellation levels, with management indicating that cancellations were at the highest level compared to the previous year [5]. - The CEO described cancellations as "broad-based" without providing clear answers on the causes, leaving investors uncertain [5].

Core Insights - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. due to significant stock losses experienced by investors [2][4] - Beta Bionics' stock (NASDAQ: BBNX) dropped approximately 37% on January 9, 2026, following the company's announcement of lower-than-expected patient starts for the fourth quarter [4] Company Overview - Beta Bionics, Inc. is a publicly traded company listed on NASDAQ under the ticker BBNX [2] - The company has faced scrutiny regarding whether it issued misleading statements or failed to disclose critical information to investors [4] Legal Context - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3] - The firm is encouraging investors who have suffered significant losses in Beta Bionics to discuss their legal options [1][2]

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. due to alleged misrepresentations regarding the company's financial targets and performance, particularly in its Branded Checkout segment, leading to significant stock price decline [1][3][4]. Company Performance - PayPal's financial results for Q4 and full fiscal year 2025 were disappointing, with a notable decline in performance in the Branded Checkout segment [3]. - The company announced a sudden transition in its CEO role and withdrew its previously set financial targets for 2027, indicating a slowdown in growth expectations [3]. Stock Market Reaction - Following the announcement of poor financial results, PayPal's stock price dropped from $52.33 per share on February 2, 2026, to $41.70 per share on February 3, 2026, marking a decline of approximately 20.31% in one day [4]. Legal Action - The lawsuit, Aaron B. Goodman v. PayPal Holdings, Inc., has been initiated in the U.S. District Court for the Northern District of California, targeting investors who purchased PayPal stock between February 25, 2025, and February 2, 2026 [1][3]. - Investors are encouraged to step forward before the April 20, 2026 deadline to seek compensation for losses incurred due to the alleged misrepresentations [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Wealthfront To Contact Him Directly To Discuss Their Options If you suffered significant losses in Wealthfront stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 15, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LL ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Commvault Systems, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1]. Investigation Details - The investigation focuses on whether Commvault has engaged in unlawful business practices that may have led to financial losses for investors [2]. Financial Performance - On January 27, 2026, Commvault reported a 40% growth in SaaS ARR, totaling $364 million, but this represents a significant deceleration from the 56% growth reported in the previous quarter [6]. - Following the financial results announcement, Commvault's stock price fell by $40.23 per share, approximately 31.1%, from $129.36 on January 26, 2026, to $89.13 on January 27, 2026 [6].

Core Viewpoint - Stellantis N.V. is under investigation for potential violations of federal securities laws following a significant decline in stock value after a major announcement regarding its electric vehicle (EV) strategy and financial performance [1][4]. Group 1: Timeline of Events - On January 31, 2026, Wall Street Zen downgraded Stellantis to Sell, followed by Morgan Stanley's downgrade to Equal-Weight on February 3, citing an "investment lag" [2]. - A report on February 5 indicated Stellantis was seeking European cash to mitigate tariff-related challenges, suggesting cash-flow stress [2]. - The last earnings call was over 90 days old by the time of the February 6 announcement, with no interim updates addressing the deteriorating EV program assumptions that led to a $22 billion charge [2]. Group 2: February 6 Announcement - The February 6 announcement revealed that management had overestimated the pace of EV adoption, leading to a strategic reset that included suspending the 2026 dividend and reviewing the dividend policy [3]. - Following this announcement, shares of Stellantis fell approximately 28% in a single trading session, marking one of the worst trading days in the company's history [3]. Group 3: Investigation Focus - The investigation is centered on whether Stellantis' public communications between the Q3 2025 earnings call and the February 6 disclosure accurately reflected the company's internal understanding of the viability and valuation of its EV assets [4].